English
Segment disclosures
Company overviewSTREAMEX CORP.
Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.
Revenue · Reported segment facts
Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.
Product · Neuro Clear Technologies Inc Neuro Clear
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=us-gaap:ProductMember;us-gaap:StatementBusinessSegmentsAxis=bsgm:NeuroClearTechnologiesIncNeuroClearMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-07-01 – 2021-09-30 | 0 | USD | 20211115 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 0 | USD | 20211115 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 0 | USD | 20210811 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 0 | USD | 20210811 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 0 | USD | 20210517 | Open filing evidence |
Product · Viral Clear
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=us-gaap:ProductMember;us-gaap:StatementBusinessSegmentsAxis=bsgm:ViralClearMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-07-01 – 2021-09-30 | 0 | USD | 20211115 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 0 | USD | 20211115 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 0 | USD | 20210811 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 0 | USD | 20210811 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 0 | USD | 20210517 | Open filing evidence |
Product · Corporate
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=us-gaap:ProductMember;us-gaap:StatementBusinessSegmentsAxis=us-gaap:CorporateMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-07-01 – 2021-09-30 | 100000 | USD | 20211115 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 414000 | USD | 20211115 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 199000 | USD | 20210811 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 314000 | USD | 20210811 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 115367 | USD | 20210517 | Open filing evidence |
Service · Neuro Clear Technologies Inc Neuro Clear
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=us-gaap:ServiceMember;us-gaap:StatementBusinessSegmentsAxis=bsgm:NeuroClearTechnologiesIncNeuroClearMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-07-01 – 2021-09-30 | 0 | USD | 20211115 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 0 | USD | 20211115 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 0 | USD | 20210811 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 0 | USD | 20210811 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 0 | USD | 20210517 | Open filing evidence |
Service · Viral Clear
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=us-gaap:ServiceMember;us-gaap:StatementBusinessSegmentsAxis=bsgm:ViralClearMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-07-01 – 2021-09-30 | 0 | USD | 20211115 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 0 | USD | 20211115 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 0 | USD | 20210811 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 0 | USD | 20210811 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 0 | USD | 20210517 | Open filing evidence |
Service · Corporate
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=us-gaap:ServiceMember;us-gaap:StatementBusinessSegmentsAxis=us-gaap:CorporateMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-07-01 – 2021-09-30 | 8000 | USD | 20211115 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 19000 | USD | 20211115 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 8000 | USD | 20210811 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 11000 | USD | 20210811 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 2680 | USD | 20210517 | Open filing evidence |
Bio Sig AI
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=bsgm:BioSigAIMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-04-01 – 2023-06-30 | 0 | USD | 20230814 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 0 | USD | 20230814 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 0 | USD | 20230814 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 0 | USD | 20230814 | Open filing evidence |
Neuro Clear Technologies Inc Neuro Clear
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=bsgm:NeuroClearTechnologiesIncNeuroClearMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-03-31 | 0 | USD | 20230515 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 0 | USD | 20230331 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 0 | USD | 20221114 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 0 | USD | 20221114 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 0 | USD | 20220815 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 0 | USD | 20220815 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 0 | USD | 20230515 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 0 | USD | 20230331 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 0 | USD | 20221114 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 0 | USD | 20221114 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 0 | USD | 20220815 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 0 | USD | 20220815 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 0 | USD | 20220516 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 0 | USD | 20220331 | Open filing evidence |
Viral Clear
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=bsgm:ViralClearMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-04-01 – 2023-06-30 | 0 | USD | 20230814 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 0 | USD | 20230814 | Open filing evidence |
| 2023-01-01 – 2023-03-31 | 0 | USD | 20230515 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 0 | USD | 20230331 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 0 | USD | 20221114 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 0 | USD | 20221114 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 0 | USD | 20230814 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 0 | USD | 20230814 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 0 | USD | 20230515 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 0 | USD | 20230331 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 0 | USD | 20221114 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 0 | USD | 20221114 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 0 | USD | 20220815 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 0 | USD | 20220815 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 0 | USD | 20220516 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 0 | USD | 20220331 | Open filing evidence |
Viral Clear Pharmaceuticals Inc
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=BSGM:ViralClearPharmaceuticalsIncMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-06-30 | 13000 | USD | 20250815 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 27000 | USD | 20250815 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 14000 | USD | 20250519 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 18000 | USD | 20250415 | Open filing evidence |
Corporate
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=us-gaap:CorporateMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | -146000 | USD | 20260814 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | -146000 | USD | 20260814 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 40000 | USD | 20260331 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 27000 | USD | 20251114 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 13000 | USD | 20240814 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 27000 | USD | 20240814 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 14000 | USD | 20240520 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 18000 | USD | 20240416 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 1000 | USD | 20241114 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 6000 | USD | 20241114 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 0 | USD | 20230814 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 5000 | USD | 20240814 | Open filing evidence |
| 2023-01-01 – 2023-03-31 | 5000 | USD | 20240520 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 286000 | USD | 20240416 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 135000 | USD | 20231114 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 151000 | USD | 20231114 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 8000 | USD | 20230814 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 16000 | USD | 20230814 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 8000 | USD | 20230515 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 441000 | USD | 20230331 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 108000 | USD | 20221114 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 433000 | USD | 20221114 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 207000 | USD | 20220815 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 325000 | USD | 20220815 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 118000 Restated | USD | 20220516 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 0 | USD | 20220331 | Open filing evidence |